Treatment sequence after first-line immunotherapy in older adults with advanced NSCLC (NEJ057)
BACKGROUND: Optimal management of older patients with advanced non-small cell lung cancer (NSCLC) following progression on immune checkpoint inhibitors (ICIs) remains uncertain, as large-scale evidence guiding second-line therapy in this population is limited. However, the efficacy of single-agent chemotherapy as second-line treatment was comparable to real-world outcomes reported prior to ICIs.
BACKGROUND: Optimal management of older patients with advanced non-small cell lung cancer (NSCLC) following progression on immune checkpoint inhibitors (ICIs) remains uncertain, as large-scale evidence guiding second-line therapy in this population is limited. However, the efficacy of single-agent chemotherapy as second-line treatment was comparable to real-world outcomes reported prior to ICIs.
What the study was
- Study design
- Multicenter cohort study
- Population
- Patients
- Sample size
- 1245
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- International journal of clinical oncology
Why it surfaced
Matched Novel therapeutics; Multicenter cohort study; human study; score 9/10 (n=2 r=3 dq=2 pop=2)
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.